• toxicity
  • Myocardial toxicity, manifested in its most severe form by potentially fatal congestive heart failure (CHF), may occur either during therapy with epirubicin or months to years after termination of therapy. (nih.gov)
  • cycles
  • Primarily, this clinical investigation compares the rates (percentages) of pathological complete remissions attained at the time of final surgery following 6 cycles each of epirubicin + do. (bioportfolio.com)
  • given
  • Epirubicin is always given under the supervision of a doctor in a hospital or similar setting with access to sterile equipment for preparation. (pharmasave.com)